Biofrontera (NASDAQ:BFRI) Stock Rating Upgraded by Zacks Research

Biofrontera (NASDAQ:BFRI) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

A number of other equities analysts also recently weighed in on the company. Wall Street Zen upgraded Biofrontera to a “hold” rating in a research note on Saturday, July 18th. Weiss Ratings raised Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Biofrontera has a consensus rating of “Hold”.

Biofrontera Price Performance

BFRI opened at $1.22 on Monday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.20 and a quick ratio of 1.09. The firm’s fifty day moving average price is $1.03 and its two-hundred day moving average price is $0.96. Biofrontera has a 1 year low of $0.55 and a 1 year high of $1.27. The company has a market capitalization of $15.62 million, a price-to-earnings ratio of -1.26 and a beta of 0.78.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.29). Biofrontera had a negative return on equity of 515.34% and a negative net margin of 25.66%.The firm had revenue of $10.08 million for the quarter, compared to analysts’ expectations of $10.25 million. As a group, analysts anticipate that Biofrontera will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. grew its holdings in shares of Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 976,448 shares of the company’s stock after purchasing an additional 332,055 shares during the quarter. Biofrontera comprises approximately 0.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th biggest holding. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.08% of the company’s stock.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.